Drugs Made In America Acquisition Corp. (DMAAR) Notes Payables (2024 - 2026)

Drugs Made In America Acquisition (DMAAR) has reported Notes Payables for 3 consecutive years, with $350000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Notes Payables changed N/A year-over-year to $350000.0; the trailing twelve-month figure through Jun 2026 stood at $350000.0 (changed N/A YoY), and the FY2024 full-year result was $662324.0, changed N/A from the prior year.
• Notes Payables rose to $350000.0 in Q2 2026 per DMAAR's latest filing, from $60898.0 in the prior quarter.
• Across five years, Notes Payables topped out at $662324.0 in Q4 2024 and bottomed at $60898.0 in Q1 2025.
• Historically, Notes Payables has averaged $357740.7 across 3 years, with a median of $350000.0 in 2026.